Navigation Links
ASCO Interview of MD Anderson's Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites
Date:6/13/2013

WORCESTER, Mass. and TORONTO, June 13, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that the interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. to Oncology TV at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) in respect of the Antigen Express (www.antigenexpress.com) AE37 breast cancer vaccine is now available on the Generex and Antigen Express websites, together with the abstracts related thereto.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
2. Interviews Of NW Bios CEO, On The Floor Of The New York Stock Exchange, Now Available Online
3. GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
4. Breaking News: Video Interview With Harry Zhabilov of Immunotech Laboratories Inc.
5. Aethlon Medical Discloses CEO Interview
6. Mike Dixon Says the Job of Integrating Services is Far From Over in Interview on ITNs Healthcare Channel
7. Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
8. Griffin Securities Analyst Interviews Unilife Corp. CEO in a Two-Part Video Series
9. GSK CEO Sir Andrew Witty Interviewed on Q2 2012 Results
10. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
11. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At SmallCapVoice.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare ... conditions, announced today that the Company will present its ... on Tuesday, February 16, 2016, at 4:30 p.m. ET.  ... overview of its business and growth strategy, as well ... 31, 2015. --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development of a once-daily, oral therapy for ... Chief Medical Officer, Dr. Maya Halpern , has notified ... Chief Medical Officer and from its Board of Directors ... reaching retirement age. Allen Baharaff . Mr. ...
(Date:2/11/2016)... , February 11, 2016 ... Autoclave Market Report 2016 research report provides information ... regions, development status with crucial statistical data and ... http://www.deepresearchreports.com/142870.html . --> Complete report ... 19 companies and supported with 296 tables and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today ... Practice , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, ... , During his session, “ Coding for Care: Using Data Analytics for Risk ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Be ... new office in the heart of Old Town at 108 South Columbus St, Suite ... businesses the highest level of medical care in the convenience of their homes, offices ...
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/10/2016)... Los Angeles, CA (PRWEB) , ... February 10, ... ... Neuro-Linguistic Programming (NLP) practitioner, is known locally for a series of therapeutic sessions ... be in-the-moment in their characters and in their lives. The series, known as ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... company is unveiling its revolutionary new 2.0 version at the International Roofing Expo ... “put the power of the world's most advanced weather technology in the hands ...
Breaking Medicine News(10 mins):